The detection of the BCR-ABL fusion gene has significant clinical implications. Firstly, it confirms the diagnosis of CML, distinguishing it from other types of leukemia. Secondly, it has prognostic value; patients with the Philadelphia chromosome-positive CML generally have a more predictable disease course and response to certain treatments. Lastly, the BCR-ABL oncogene is a prime target for molecularly targeted therapies.
